Funds and ETFs Exscientia plc

Equities

EXAI

US30223G1022

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
4.03 USD +1.00% Intraday chart for Exscientia plc -4.95% -37.13%

ETFs positioned on Exscientia plc

Name Weight AuM 1st Jan change Investor Rating
0.04% 0 M€ 0.00% -
Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Precision Target, Precision Design, Precision Experiment, Precision Medicine, Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.235 GBP
Average target price
6.873 GBP
Spread / Average Target
+112.44%
Consensus
  1. Stock Market
  2. Equities
  3. EXAI Stock
  4. Funds and ETFs Exscientia plc